Sustained release composition and manufacturing method thereof
A sustained release composition comprising a polymer and manufacturing method thereof. The sustained release composition comprises a polymer, a bioactive agent, and a release rate determined agent, wherein the release rate determined agent is dispersed in the sustained release composition to control the release rate of the bioactive agent. The method comprises providing an oil phase comprising a bioactive agent, a polymer, and a release rate determined agent; providing an aqueous phase comprising a surfactant; mixing the oil phase with the aqueous phase to form the sustained release composition having a controlled release effect.
1. A sustained release composition without lag phase comprising a polymer, a bioactive agent, and a release rate determined agent, wherein the bioactive agent and the release rate determined agent are dispersed in the sustained release composition, the release rate determined agent is vitamin E-TPGS present in amounts of 7%-42% by weight of the total weight of the sustained release composition for controlling the release rate of the bioactive agent,
wherein the polymer is polylactide-co-glycolide (PLGA) and the bioactive agent is olanzapine, and
wherein the sustained release composition is produced by an emulsion process comprising an oil phase including the bioactive agents, the polymer and the release rate determined agent before mixing with an aqueous phase.
2. The sustained release composition as claimed in claim 1 , wherein the sustained release composition continually releases the bioactive agent.
3. The sustained release composition as claimed in claim 1 , wherein the sustained release composition has an encapsulation rate of bioactive agent exceeding 70%.
4. The sustained release composition as claimed in claim 1 , wherein the sustained release composition is a microsphere, microparticle, or microcapsule.
5. The sustained release composition as claimed in claim 4 , wherein the microsphere, microparticle, or microcapsule has a diameter exceeding 5 μm.
6. The sustained release composition as claimed in claim 1 , wherein the sustained release composition is used for intramuscular or subcutaneous injection.
7. A method for manufacturing a sustained release composition as claimed in claim 1 , comprising:
(a) providing an oil phase comprising olanzapine, polylactide-co-glycolide (PLGA), and vitamin E-TPGS;
(b) providing an aqueous phase comprising a surfactant;
(c) mixing the oil phase with the aqueous phase to form the sustained release composition; and
(d) recovering the composition.
8. The method as claimed in claim 7 , wherein the oil phase further comprises a solvent.
9. The method as claimed in claim 8 , wherein the solvent comprises methylene chloride, ethyl acetate, benzyl alcohol, acetone, acetic acid, propylene carbonate, dichloromethane, chloroform, 1,4-dioxane, dimethylformamide (DMF), dimethyl sulphoxide (DMSO), toluene, or tetrahydrofuran (THF).
10. The method as claimed in claim 7 , wherein the surfactant comprises polyvinyl alcohol (PVA), NP-5, Triton x-100, Tween 80, PEG 200-800, sodium dodecyl sulfate (SDS), alcohol ethoxylates, alkylphenol ethoxylates, secondary alcohol ethoxylates, fatty acid ester, or alkyl polyglycosides.
11. The method as claimed in claim 7 , wherein the release rate determined agents has a final concentration of about 7 to 42% by weight.
12. The method as claimed in claim 7 , wherein the sustained release composition is a microsphere, microparticle, or microcapsule.